Comparison of Chromogenic in Situ Hybridization with Other Methodologies for HER2 Status Assessment in Breast Cancer

Overview

Journal J Mol Histol

Specialty Biochemistry

Date 2004 Dec 23

PMID 15614619

Citations 10

Authors

Cornelia Hauser-Kronberger

Nadia Dandachi

Affiliations

Soon will be listed here.

Abstract

The high incidence of human epidermal growth factor receptor (HER)2 overexpression on breast and various other cancer cells and the prognostic and potentially predictive value of HER2 render this growth receptor a novel and important therapeutic target. Out of a wide range of assays that have been used in research for the detection of HER2 status, only two techniques are now predominant and readily applicable in the routine clinical pathology laboratory: determination of HER2 overexpression by immunohistochemistry (IHC) and HER2 gene amplification by fluorescence in situ hybridisation (FISH). In a retrospective study on a cohort of 173 archival invasive breast carcinomas a chromogenic in situ hybridisation (CISH) assay for the detection of HER2 amplification was established. Results were compared to HercepTest, which is the most frequently used method for detecting HER2 alteration. Additionally, HER2 gene copy number was investigated using differential PCR (dPCR) as a testing system. Discrepant cases between CISH and HercepTest and all IHC positive cases (2 + and 3 +), a total of 42 cases, were analysed with FISH Path Vysion(Vysis) assay. HER2 overexpression was found by IHC in 24.3%, HER2 amplification by CISH in 19.1% and by dPCR in 9.2% of the tumours. The overall concordance rate between CISH and IHC was 95.9%, between dPCR and IHC 85% and between CISH and FISH 100%, respectively. Among 25 HercepTest positive cases (score 3+) two showed no gene amplification and four out of 13 tumours with score 2 + were negative with CISH and FISH. The current study showed that CISH offers an ideal approach that allows detection of HER2 amplification in the context of morphology, whereas the major drawback of dPCR is the impracticability of tissue differentiation of invasive and non-invasive carcinoma.

Citing Articles

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables.

A Musa Z, J Qasim B, A K Al Shaikhly A Iran J Pathol. 2018; 12(1):9-19.

PMID: 29760748 PMC: 5938719.

Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.

Rosa F, Santos R, Rogatto S, Domingues M Braz J Med Biol Res. 2013; 46(3):207-16.

PMID: 23558859 PMC: 3854374. DOI: 10.1590/1414-431x20132483.

The 70-gene prognostic signature for korean breast cancer patients.

Na K, Kim K, Lee J, Kim H, Yang J, Ahn S J Breast Cancer. 2011; 14(1):33-8.

PMID: 21847392 PMC: 3148507. DOI: 10.4048/jbc.2011.14.1.33.

Development of Targeted Therapies in ErbB2-Positive Breast Cancer.

Jackisch C, Ruschoff J, Ullrich A Breast Care (Basel). 2010; 3(s1):3-6.

PMID: 20824001 PMC: 2930989. DOI: 10.1159/000119745.

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S J Cancer Res Clin Oncol. 2010; 137(2):261-9.

PMID: 20396915 DOI: 10.1007/s00432-010-0881-0.

References

Schnitt S, Jacobs T . Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2002; 116(6):806-10. DOI: 10.1309/WMN8-VTR5-DUGF-X12L. View

Press M, Bernstein L, Thomas P, Meisner L, Zhou J, Ma Y . HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997; 15(8):2894-904. DOI: 10.1200/JCO.1997.15.8.2894. View

Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F . HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003; 9(10 Pt 1):3645-52. View

Foy C, Parkes H . Emerging homogeneous DNA-based technologies in the clinical laboratory. Clin Chem. 2001; 47(6):990-1000. View

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart M . Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000; 157(5):1467-72. PMC: 1885742. DOI: 10.1016/S0002-9440(10)64785-2. View

Dowsett M, Bartlett J, Ellis I, Salter J, Hills M, Mallon E . Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003; 199(4):418-23. DOI: 10.1002/path.1313. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Tubbs R, Pettay J, Roche P, Stoler M, Jenkins R, Grogan T . Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001; 19(10):2714-21. DOI: 10.1200/JCO.2001.19.10.2714. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

10.

Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R . Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 1999; 45(8 Pt 1):1148-56. View

11.

Pauletti G, Godolphin W, Press M, Slamon D . Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13(1):63-72. View

12.

LYON E, Millson A, Lowery M, Woods R, Wittwer C . Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem. 2001; 47(5):844-51. View

13.

Bartlett J, Going J, Mallon E, Watters A, Reeves J, Stanton P . Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001; 195(4):422-8. DOI: 10.1002/path.971. View

14.

Dandachi N, Dietze O, Hauser-Kronberger C . Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002; 82(8):1007-14. DOI: 10.1097/01.lab.0000024360.48464.a4. View

15.

Watters A, Going J, Cooke T, Bartlett J . Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003; 77(2):109-14. DOI: 10.1023/a:1021399923825. View

16.

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V . Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003; 9(3):923-30. View

17.

Tubbs R, Skacel M, Pettay J, Powell R, Myles J, Hicks D . Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol. 2002; 26(7):908-13. DOI: 10.1097/00000478-200207000-00009. View

18.

Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg M . Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn. 2003; 5(3):184-90. PMC: 1907331. DOI: 10.1016/S1525-1578(10)60471-0. View

19.

Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z . Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002; 15(6):657-65. DOI: 10.1038/modpathol.3880582. View

20.

Tubbs R, Pettay J, Skacel M, Powell R, Stoler M, Roche P . Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol. 2002; 160(5):1589-95. PMC: 1850888. DOI: 10.1016/S0002-9440(10)61106-6. View